Biotech Values

[DewDiligence]

Hmm… (from today’s Alcon CC)

Alcon’s head of R&D, Jerry Cagle, divulged that Alcon is pursuing “backup compounds” to supplement Alcon’s AMD program and will have a significant announcement in the near future. Whether this refers to backup in-house compounds or to acquisitions he didn’t say.

Based on the CC, it appears to me that the chance of Retaane being approved by the FDA without a substantial delay is small. Although the FDA agreed to review Alcon’s NDA, the FDA did not actually request that Alcon submit an NDA, a distinction that I and some of the analysts on the CC found significant.

Moreover, there were some details on the CC which made the Retaane data appear even more tenuous than what I had expected based on Alcon’s PR two days ago (#msg-4284803). I’ll be glad to provide details if anyone is interested.